UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

The New England journal of medicine, 2023-07, Vol.389 (2), p.137-147

2023

Volltextzugriff (PDF)

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

The lancet oncology, 2020-03, Vol.21 (3), p.373-386

2020

Volltextzugriff (PDF)

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3327-3334

2013

Volltextzugriff (PDF)

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Volltextzugriff (PDF)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Cancer discovery, 2022-01, Vol.12 (1), p.74-89

2022

Volltextzugriff (PDF)

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The lancet oncology, 2015-02, Vol.16 (2), p.141-151

2015

Volltextzugriff (PDF)

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

The lancet oncology, 2012-05, Vol.13 (5), p.539-548

2012

Volltextzugriff (PDF)

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

Cancer medicine (Malden, MA), 2023-04, Vol.12 (7), p.8838-8850

2023

Volltextzugriff (PDF)

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

Scientific reports, 2022-02, Vol.12 (1), p.3319-3319, Article 3319

2022

Volltextzugriff (PDF)

Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study

BMC cancer, 2024-07, Vol.23 (Suppl 1), p.1250-12, Article 1250

2024

Volltextzugriff (PDF)

Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway

American journal of respiratory cell and molecular biology, 2013-08, Vol.49 (2), p.241-250

2013

Volltextzugriff (PDF)

Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial

BMC cancer, 2024-08, Vol.24 (1), p.1006-13, Article 1006

2024

Volltextzugriff (PDF)

IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer

Cell death & disease, 2024-05, Vol.15 (5), p.356-13, Article 356

2024

Volltextzugriff (PDF)

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

International journal of nanomedicine, 2012-01, Vol.7 (default), p.4269-4283

2012

Volltextzugriff (PDF)

PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target

Cell death & disease, 2023-10, Vol.14 (10), p.671-17, Article 671

2023

Volltextzugriff (PDF)

Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells

Biochemical pharmacology, 2012-05, Vol.83 (9), p.1159-1171

2012

Volltextzugriff (PDF)

Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

Scientific reports, 2023-03, Vol.13 (1), p.3943-3943, Article 3943

2023

Volltextzugriff (PDF)

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1718-1732

2021

Volltextzugriff (PDF)

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1580-1590

2020

Volltextzugriff (PDF)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment

Cancer medicine (Malden, MA), 2019-10, Vol.8 (13), p.5939-5947

2019

Volltextzugriff (PDF)

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Journal of thoracic oncology, 2019-03, Vol.14 (3), p.553-559

2019

Volltextzugriff (PDF)

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1105-1115

2023

Volltextzugriff (PDF)

Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells

Carcinogenesis (New York), 2012-11, Vol.33 (11), p.2065-2075

2012

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

SpracheRussisch

ThemaLung Neoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Humans
(64)
Science & Technology
(59)
Life Sciences & Biomedicine
(57)
Oncology
(45)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(43)
Female
(41)
Male
(37)
Lung Neoplasms - Genetics
(36)
Middle Aged
(33)
Lung Cancer
(31)
Mutation
(30)
Aged
(28)
Lung Neoplasms - Pathology
(28)
Carcinoma, Non-Small-Cell Lung - Genetics
(25)
Erbb Receptors - Genetics
(23)
Adult
(21)
Chemotherapy
(18)
Adenocarcinoma - Drug Therapy
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study

Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway

Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial

IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target

Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells

Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells

Aktive Filter

Suchergebnisse filtern